Pfizer COVID-19 Vaccine EUA Revoked; Comirnaty BLA Takes Effect

Pfizer-BioNTech's COVID-19 vaccine EUA is no longer in force, a regulatory shift that moves all mRNA vaccine manufacturing for this product squarely under 21 CFR Part 211 and full BLA post-approval obligations. The FDA revoked the EUA on August 27, 2025, confirming that Comirnaty (COVID-19 Vaccine, mRNA), manufactured by Pfizer Inc., now operates exclusively under its approved biologics license.

For quality and compliance teams, the practical consequence is a tighter manufacturing controls environment. EUA-era flexibilities, including certain labeling accommodations, expedited deviation reporting thresholds, and streamlined comparability protocols, no longer apply. Sites producing Comirnaty must now demonstrate full conformance with BLA-committed processes, and any post-approval manufacturing changes require prior approval or annual report submissions consistent with 21 CFR Part 601 and ICH Q10 quality system expectations.

The revocation follows a formal granting letter issued as recently as June 25, 2025, which updated fact sheets for both recipients and healthcare providers under the still-active EUA at that time. The August 27 revocation letter and accompanying memorandum close that authorization entirely, leaving no parallel EUA pathway for this product. Regulatory affairs leads should confirm that all distributed labeling, including multilingual fact sheets previously issued under EUA, is withdrawn from active use and replaced with BLA-approved labeling.

Read against the broader mRNA regulatory landscape, this action mirrors parallel EUA revocations for Moderna's COVID-19 vaccine, signaling that FDA considers the emergency-use framework for mRNA COVID-19 vaccines fully exhausted. For plant heads managing shared mRNA manufacturing infrastructure, the compliance posture now demands that batch records, process validation documentation, and annual product reviews reflect BLA-standard rigor with no residual EUA carve-outs.

The next measurable checkpoint for affected sites is a full audit of change control logs to confirm that any manufacturing or formulation changes implemented under EUA flexibility have been bridged into the BLA record through appropriate Prior Approval Supplements or Changes Being Effected submissions.

Source: FDA Vaccines, Blood and Biologics RSS Feed via FDA.gov, August 27, 2025.